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Introduction
Notwithstanding the great progress made in the treatment
of cancer pain, not all patients can be treated satisfactori-
ly. In particular, neuropathic pain and incidence pain as
encountered in nervous compression or pathological bone
fracture can be notoriously difficult to control. Basically,
pain treatment in these cases consists of a combination of
analgesics according to the WHO-ladder and co-anal-
gesics. When this approach is insufficient, continuous
subcutaneous, intravenous or spinal infusion techniques
can be applied in addition. Nevertheless, some patients
fail to respond to these therapies and continue to be dis-
satisfied.
When in these cases pain is localised, predominantly
unilaterally, the application of percutaneous cervical cord-
otomy (PCC) can be a valuable additional measure. In
case of midline or bilateral pain, continuous spinal infu-
sion techniques are preferred for further pain control [1].
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Abstract The results obtained by
percutaneous cervical cordotomy
(PCC) were analysed in 43 termi-
nally ill cancer patients treated in
our institution from 1998 to 2001.
We wished to determine whether
there is still a place for PCC in the
actual clinical situation with its
wide choice of pain therapies. All
patients had severe unilateral pain
due to cancer, resistant to opioids
and co-analgesics. Following PCC,
mean pain intensity was reduced
from Numeric Rating Scale (NRS)
7.2 to 1.1. At the end of life, pain
had increased to NRS 2.9. Initially
following PCC a good result
(NRS<3) was obtained in 95% of
patients. At the end of life, a good
result was still present in 69% of
patients. Mean duration of survival
after the intervention was 118 days
(2–1460). In general, complications
were mild and mostly subsided
within 3–4 days. There was one
case of partial paresis of the ipsilat-
eral leg. PCC remains a valuable
treatment in patients with treat-
ment-resistant cancer pain and still
deserves a place in the treatment of
terminal cancer patients with severe
unilateral neuropathic or incidence
pain.
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PCC was introduced in 1965 by Mullan and Rosomoff
for the treatment of unilateral intractable cancer pain.
PCC consists of a percutaneously applied interruption of
the spinothalamic tract in the spinal cord at the spinal
level CI–II [2]. Until the mid-1980s the method was fre-
quently applied and was considered as a major tool in the
treatment of severe cancer pain, but its popularity
decreased considerably due to the availability of oral and
transdermal analgesic therapy. Following the introduction
of continuous spinal infusion techniques, a further decline
occurred in the number of patients treated [3]. This article
tries to answer the question whether there is still a place
for PCC within the wide array of the actual therapeutic
possibilities by analysing the results obtained in our insti-
tution with 43 terminally ill cancer patients suffering from
intractable unilateral pain and submitted to PCC. All these
patients had full access to anticancer therapies and current
analgesic measures.
Patients and methods
In a retrospective study the records of all patients (n=43) who
underwent a PCC during the period 1998–2001 in our institu-
tion, were analysed (see Table 1). Approval was obtained from
the hospital ethical commission.
Registered were demographics, primary tumour, Karnofsky
performance status scale (Karnofsky Index rating from 0 to 100,
0=dead, 100=no complaints), sites of pain, type of pain, duration
of pain prior to PCC, the duration of treatment in our institution
prior to PCC, intake of opioids before and following PCC and
before death, Numeric Rating Scores (NRS, 0=no pain, 10=pain
as bad as imaginable) before and after PCC and before death,
duration of effect, side effects and complications. Treatment
consisted of a multimodal therapeutic approach including med-
ical, psychosocial and spiritual aspects.
Before PCC, patients were treated according to the WHO-
ladder. Opioids were titrated to the level for obtaining satisfac-
tory pain relief or the occurrence of unacceptable side effects.
The majority of patients (30/43) suffered from neuropathic pain
insufficiently relieved by a combination of tricyclic antidepres-
sants and anticonvulsants. Incidence pain or pain on movement
was present in 23/43 patients.
Previous to PCC, continuous spinal infusion techniques were
applied in 7 patients. Two patients received an epidural infusion
and 5 patients intrathecal infusions with a combination of mor-
phine and bupivacaine.
Patients were offered the possibility of PCC when they suf-
fered from unilateral pain below the spinal segment C5, not
responding to maximal symptomatic therapy as mentioned
above.
Contraindications were blood coagulation disorders, severe-
ly reduced ventilatory functions (FEV1<12 ml/kg BW) and pre-
sumed inability of the patient to cooperate during the procedure.
PCC was carried out by using a two-needle technique. Under
direct lateral vision by use of a C-arm image intensifier, a 22
gauge spinal needle is inserted at the level C1–C2 to reach the
anterior part of the intrathecal space. Once the needle is inside
the intrathecal space, a contrast dye (Lipiodol Ultrafluide,
Guerbet Laboratoires, 93600 Aulnay-sur-Blois, France) is inject-
ed and three lines become visible: the most anterior line shows
the delineation of the anterior border of the spinal cord, the sec-
ond line represents the dentate ligament and finally the third line
is the projection of the posterior dura mater. The spinothalamic
tract is positioned just anterior to the dentate ligament. Now a
20-gauge needle allowing the introduction of a Levin thermo-
couple electrode is aimed just anterior to the dentate ligament,
the position of the spinothalamic (pain) tract (Radionics,
Burlington, MA, USA). After introduction of the tip of the elec-
trode into the spinal cord, stimulation is performed using cur-
rents with frequencies of 2 Hz and 50 Hz. Stimulation with 2 Hz
generally provokes contractions of the longus colli musculature
at 0.5–1 V. Any other contractions are an indication that the tip
of the electrode is in the corticospinal (motor) tract. A lesion
here would provoke a paresis of the interested muscles.
Repositioning of the needle more anteriorly is needed. Sensory
tracts are identified by 50 Hz stimulation. When the tip of the
electrode is inside the spinothalamic tract, intensities of 0.1–0.3
V can provoke temperature sensations (warmth or cold) in the
corresponding part of the contralateral body half. After meticu-
lous assessment of the correct position of the electrode tip by
repeated stimulation, a radiofrequency lesion is made resulting
in a tip temperature of 90°C for 10 s. Directly following the
lesioning, pinprick tests are performed to assess the eventual
occurrence of an eventual analgesic area. The technique is
described extensively elsewhere [4].
When appropriate, remifentanil was administered intra-
venously for the reduction of apprehension and stress or to make
a recumbent position of the patient possible. A starting dose of
remifentanil 3–4 µg/kg BW in 4–5 min was given followed by a
continuous intravenous infusion of remifentanil 0.2–0.3 µg/kg
BW/min.
If needed, a continuous intravenous infusion of propofol 2–4
µg/kg BW/min was added. Oxygen was added by a nasal
catheter 1–2 l/min. Monitoring consisted of EKG and pulse
oximetry. Care was taken to ensure that patients were still able
to communicate verbally during the whole procedure. The mean
duration of PCC was approximately 40 min.
Table 1 Demographic data (n=43, male=32)
Median Range Mean SD
Age, years 59.30 29.3–85.8 59.20 12.81
Duration of 6.00 0.3–31.0 8.00 6.75
symptoms, months
Duration of 1.50 0.1–20.0 3.38 4.86
treatment, months
Karnofsky index, mean 60.00 30.0–90.0 60.20 16.00
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Results
Table 2 gives an overview of all patients with diagnosis,
pain type, intake of opioids before PCC and after PCC and
NRS rating before PCC, after PCC, and before death. Two
patients died within one week following PCC. Death was
not directly related to PCC.
Directly following PCC, 41/43 patients reported a
good result (NRS≤4). During follow up until death, 34/40
patients in our series submitted to PCC obtained good
pain control (NRS≤4) (Tables 3 and 4).
In four patients (patient numbers 6, 21, 33 and 42),
PCC had to be repeated within one month due to incom-
plete blockade. In three patients this was successful. The
Table 2 Overview of patients
Number Age at Diagnosis Pain type Localisation Karnofsky Opioids Opioids NRS# NRS NRS Survival Spinal Spinal Remarks
cord. of pain index§ before after before after last inf. pre inf. post 
(years) PCC PCC
1 71.7 Mesothelioma CS, IN R flank 50 400 120 8 2 4 46
2 66.7 Mesothelioma CV, CN L flank 80 300 0 7 0 1 114
3 64.0 Mesothelioma CN R chest 80 420 120 5 0 347
4 75.0 Mesothelioma CS, IN L chest, 70 492 720 8.5 0 2 94 Mirror
sternum pain
5 74.7 Bronchial CS R flank, 60 30 0 8 2 110 Weakness 
carcinoma shoulder L leg
6 61.4 Bronchial IV R chest 90 60 60 8 0 0 363 PCC
carcinoma
7 50.5 Bronchial CN L chest, 50 90 90 7 0 4 36
carcinoma back
8 57.8 Bronchial CN L chest 30 720 240 6 0 0 6 IT
carcinoma
9 76.6 Bronchial CN L arm, 70 150 0 9 0 0 40
carcinoma chest
10 48.5 Bronchial CS R afilla, 60 600 360 6 4 4 19
carcinoma L chest
11 70.5 Bronchial IS L shoulder 60 75 0 7.5 0 6 214 Epidural
carcinoma Epidural
12 36.0 Bronchial CV R romp 70 150 90 8.5 6 3 99 Weakness 
carcinoma L leg
13 59.1 Bronchial CS L chest, 30 600 30 8 0 0 6
carcinoma R leg
14 54.7 Bronchial CN R pelvis 60 90 0 8 0 0 3
carcinoma
15 66.2 Bronchial CS, IN L shoulder, 70 440 110 7 0 2 83 Mirror 
carcinoma arm pain
16 53.0 Breast CS, IN L, R chest, 30 380 15 8 3 7 68 Mirror 
carcinoma L groin pain
17 41.9 Malignant CV R chest, 60 200 120 5.5 0 4 1381 IT IT Brief 
thymoma groin apnoea,
mirror 
pain
18 66.8 Carcinomatous IN L chest, 60 225 0 5 2 2 417
pleurisy shoulder
19 59.3 Rectal CN, IN L arm, 60 22.5 22.5 10 2 1 14 Weakness
carcinoma back R leg
20 71.5 Rectal CN Rectum, 70 120 90 4 0 2 106
carcinoma R leg
21 68.3 Colon CN R leg, 70 110 0 9 2 3 307 PCC
carcinoma groin
22 50.1 Colon IN L upper 50 450 0 5 1 3 421 IT PCC
carcinoma leg
23 69.5 Colon CN R abdomen 40 90 60 8 0 1 82 IT
carcinoma
Cont. 
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Cont. Table 2
Number Age at Diagnosis Pain type Localisation Karnofsky Opioids Opioids NRS# NRS NRS Survival Spinal Spinal Remarks
cord. of pain index§ before after before after last inf. pre inf. post 
(years) PCC PCC
24 54.0 Colon CN L leg, 80 120 0 7 0 4 298 IT
carcinoma sacrum
25 82.7 Colon CS L flank, 70 440 120 9 0 4.5 255
carcinoma ribs
26 71.9 Prostate CS L leg 60 120 120 8 0 0 8 Temporary 
carcinoma confusion
27 85.8 Prostate CN L sacrum 30 0 0 7 1 4 61 IT
carcinoma
28 61.6 Prostate CV, IN L leg, 50 90 30 8 0 191
carcinoma shoulder
29 66.7 Bladder IN L groin 70 60 24 9 3 2 18
carcinoma
30 60.1 Bladder IN R back, 40 510 510 9 0 8 10 IT Mirror 
carcinoma leg pain
31 54.4 Endometrial IS L leg, 40 135 90 9 0 1 130 IT Opioid 
carcinoma flank withdrawal
32 60.6 Penile CN L chest, 60 90 0 5 0 0 22 Weakness 
carcinoma upper leg R arm
33 63.6 Melanoma CS, IN L leg, 60 240 120 6 0 6 108 IT, PCC
groin
34 53.0 Melanoma IN L leg, 80 210 60 7 0 39
arm, back
35 29.3 Melanoma CS, IN L knee, 60 127 90 7 2 1 111 Weakness
flank R leg
36 55.7 Plasmocytoma CN, IN R flank, 90 270 60 3 0 7 151 Mirror 
chest pain
37 50.0 Nasopharyngeal IN R chest 50 412.5 412.5 7 4 1 41 IT IT, Mirror 
carcinoma PCC pain
38 31.8 Non Hodgkin IN R leg 60 935 935 8.5 6 7 25
lymphoma
39 36.7 Chondrosarcoma IS, CN R leg 40 60 0 8 4 0 454 PCC
40 57.5 Adenocarcinoma* CV R flank 90 240 60 8 0 2 68
41 50.5 Adenocarcinoma* CS R leg 70 200 200 6 0 3 27 Bladder 
dysfunction
42 46.2 Adenocarcinoma* CS, IN R hip, 60 180 180 4 2 9 177 PCC
leg
43 58.3 Hepatic IV L ribs, 60 190 120 8 2 5 24 Epidural
carcinoma head
§Karnofsky index (100=no complaints, 0=dead)
#NRS (0=no pain, 10=pain as bad as imaginable)
*Unknown localisation primary tumour
C, continuous; I, Incidence pain; S, somatic; V, visceral; N, neuropathic; R, right; L, left; morphine, morphine equivalents in milligrams;
survival, survival in days after PCC; epidural, continuous epidural infusion; IT, continuous intrathecal infusion
Table 3 Mean and median NRS scores
Results Median Range Mean SD
NRS before PCC 8 3–10 7.19 1.6
NRS after PCC 0 0–6 1.10 1.7
Reduction p=0.0001 6 2–9 6.09 2.1
NRS final 2 0–9 2.90 2.5
Reduction p=0.0001 5 -5–9 4.30 3.3
Survival, days 83 3–1381 153.00 230.0
Table 4 Opioid use in morphine equivalents in milligrams
Results Median Range Mean SD
Before PCC 190 0–935 252.2 209.0
After PCC 60 0–935 125.1 194.2
Reduction p=0.0001 75 -228–570 127.1 157.4
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other patient (patient number 33) was treated with contin-
uous intrathecal infusion with morphine and bupivacaine.
Pain relief remained problematic until death. In three
patients (patient numbers 22, 37 and 39), PCC was carried
out bilaterally with good results and no complications.
The interval between the two interventions was at least
2 weeks.
Previous to PCC in five patients (numbers 8, 17, 22, 27
and 37) pain was treated by continuous intrathecal infu-
sion with inadequate results. In two patients (number 17
and 37) the infusion was continued following PCC.
Following PCC, five other patients (numbers 17, 23, 24,
30 and 31) were treated with additional continuous
intrathecal infusion.
Complications
One patient had a permanent partial loss of muscle power
in his ipsilateral lower limb. All other complications were
transient and had minimal impact on the well-being of the
patient (Table 5).
Discussion
This study underlines the fact that PPC can be a valuable
additional therapy for the control of severe unilateral can-
cer pain below the C5 level not amenable to other thera-
peutic measures, even when treated with continuous
spinal infusion of opioids and local anaesthetics. Although
complications are mostly transient, the possibility of a
permanent lesion cannot be ruled out, as one patient in our
series shows. In his case, at electrical stimulation the
spinothalamic tract appeared to be localised very closely
to the corticospinal motor tract. Inadvertently, interruption
of the spinothalamic tract by a radiofrequency lesion here
resulted in partial damage of the corticospinal tract.
Pain in patients with advanced aggressive cancer can
pose a formidable challenge to the physician. The preva-
lence of a mixture of somatic, visceral and neuropathic
pain types necessitates a tailored and individualised pain
therapy [5]. Treatment of patients with complicated pain
syndromes requires a multimodal therapeutic approach
including causal and symptomatic aspects. Symptomatic
therapy also includes supportive measures, paying close
attention to the psychosocial and spiritual needs of the
patient and her/his relatives.
Drug treatment for cancer pain is still the mainstay of
the symptomatic therapy. Studies show that the application
of the WHO guidelines and co-analgesics results in good
pain relief in 80% of patients [5]. In the remaining 20%,
oral drug therapy does not provide adequate pain relief.
When the predominant pain is located unilaterally in
such cases, PCC can be a good option.
PCC is not a panacea, but in selected cases its effect is
paramount for achieving acceptable pain relief.
It should be emphasised that prior to PCC all our
patients were in severe pain, irresolvable with the current
analgesic therapy they had received so far. PCC was
judged to be a last resort to achieve control of pain.
The use of sedation still allowing communication
between the patient and the doctor during PCC is judged
to be an important step forward. The administration of
remifentanil creates a certain “emotional detachment” for
the patient and results in far better acceptance of the pro-
cedure. When the patient experiences relief and comfort
this circumstance creates a quiet and relaxed atmosphere
in the operating theatre. Before using this type of seda-
tion, patients were often anxious and sometimes in severe
distress. This situation was worsened when maintenance
of the recumbent position for longer periods became
problematic.
In all patients suffering from an aggressive form of
cancer, various pain sites were present, located on bilater-
al locations of the body. Therefore in virtually all cases
non-opioids such as acetaminophen and NSAIDs were
continued following successful PCC. As opioids can con-
tribute to the patients’ sense of well-being, dosages were
only gradually tapered and in most cases opioids were
continued until death. The use of antidepressants and anti-
convulsants was stopped following the control of neuro-
pathic pain.
Despite PCC, it was sometimes necessary to continue
intrathecal infusion or to start a continuous intrathecal
infusion. It is our firm impression that without the avail-
ability of PCC all the patients of this series would have
suffered from severe pain (NRS 7 and up) until death,
finally requesting sedation.
The complication rate in our series was low and is in
accordance with reports in the literature [6–8].
Mirror pain was the most often encountered but could
be adequately treated with analgesics. The PCC procedure
is technically not simple and requires considerable skills
of the physician performing the procedure. Only meticu-
lous attention to detail can prevent the occurrence of neu-
rological complications. Especially the interpretation of
Table 5 Complications (n)
Mirror pain 7
Muscle weakness 2
Short lasting apnoea 1
Bladder dysfunction 1
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neurological signs followed by precise repositioning of
the electrode requires a broad experience. Not with stand-
ing these precautions, a permanent partial loss of motor
power can present, as our series demonstrates. To preserve
one’s professional expertise it is necessary to execute the
procedure on a regular basis. Given the fact that PCC is
only indicated in a small proportion of cancer patients,
execution of PCC therefore should be restricted to a lim-
ited number of centres that can act as referral centres.
Based on our experience in The Netherlands, one centre
for a population of three million seems to be reasonable.
It is concluded that PCC represents an efficacious
method of pain reduction in situations in which all other
pain therapies fail. Therefore it still deserves a place in
present cancer pain management.
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